# US 6,727,060 B2 · Analysis of HIV-1 coreceptor use in the clinical care of HIV-1-infected patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,060 B2
- Document ID: US6727060B2
- Status: Granted
- Kind: B2
- Application number: 09/963,064
- Filed: 2001-09-25
- Published: 2002-12-26
- Granted: 2004-04-27
- Earliest claimed: 2000-09-26
- Assignees: Health Research, Inc.
- Inventors: Sean Philpott; Barbara Weiser; Harold Burger; Christina Kitchen
- Web page: https://patentgrep.com/patent/US6727060B2

## CPC

- C12Q 1/703: {Viruses associated with AIDS}
- G01N 33/56988: {HIV or HTLV}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 2333/16: HIV-1, HIV-2
- G01N 2333/715: for cytokines; for lymphokines; for interferons
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time.

## Claims

### Claim 1

A method of monitoring the efficacy of antiretroviral therapy in a patient comprising quantitating usage of the CXCR4 and/or CCR5 coreceptor in a population of biological clones derived from a patient-derived acquired immunodeficiency virus primary isolate, and determining whether there has been a shift back in coreceptor usage from the CXCR4 to the CCR5 coreceptor, whereby a shift back towards CCR5 coreceptor usage indicates that the antiretroviral therapy is effective.

### Claim 2 (depends on 1)

The diagnostic method according to claim 1, wherein the acquired immunodeficiency virus is selected from the group consisting of HIV-1 and HIV-2.

### Claim 3 (depends on 1)

The method according to claim 1, wherein quantitating the population of virus using the CXCR4 and CCR5 coreceptor comprises determining the ratio of virus using the CXCR4 coreceptor compared to virus using the CCR5 coreceptor.

### Claim 4

A method of monitoring the efficacy of antiretroviral therapy in a patient comprising the steps of:
1) obtaining patient-derived acquired immunodeficiency virus;
2) deriving biological clones therefrom;
3) assaying the clones for CXCR4 coreceptor use;
4) assaying the clones for CCR5 coreceptor use; and
5) determining the ratio of virus using the CXCR4 coreceptor compared to virus using the CCR5 coreceptor;
6) Repeating steps 1 to 4 to determine a second ratio of virus using the CXCR4 coreceptor compared to virus using the CCR5 coreceptor, and
7) Comparing the first ratio to the second ratio to determine whether there has been a shift back in coreceptor usage from the CXCR4 to the CCR5 coreceptor,
whereby a shift back towards CCR5 coreceptor usage indicates that the antiretroviral therapy is effective.

### Claim 5 (depends on 4)

The diagnostic method according to claim 4, wherein the acquired immunodeficiency virus is selected from the group consisting of HIV-1 and HIV-2.

### Claim 6 (depends on 4)

The method according to claim 4, where in the patient-derived acquired immunodeficiency virus is obtained from peripheral blood.

### Claim 7 (depends on 4)

The method according to claim 4, where in the patient-derived acquired immunodeficiency virus is obtained from genital secretion.

### Claim 8 (depends on 4)

The method according to claim 4, where in the patient-derived acquired immunodeficiency virus is obtained from cerebro spinal fluid.

### Claim 9

A method of determining CXCR4 and/or CCR5 co-receptor usage in a patient before initiating antiretroviral therapy, comprising obtaining patient-derived acquired immunodeficiency virus and quantitating usage of the CXCR4 and/or CCR5 coreceptor in a population of biological clones derived from the patient-derived acquired immunodeficiency virus, whereby the CXCR4 and/or CCR5 co-receptor usage of the patient is used to determine a suitable antiretroviral treatment regimen.

### Claim 10 (depends on 9)

The diagnostic method according to claim 9, wherein the acquired immunodeficiency virus is selected from the group consisting of HIV-1 and HIV-2.

### Claim 11 (depends on 9)

The diagnostic method according to claim 9, wherein the antiretroviral therapy is selected from the group consisting of highly active antiretroviral therapy (HAART), protease inhibitors, fusion inhibitors, integrase inhibitors, coreceptor specific agents, non-nucleoside analogue reverse transcriptase inhibitors and nucleoside analogue reverse transcriptase inhibitors.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the nucleoside analogue reverse transcriptase inhibitor is 3TC.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the nucleoside analogue reverse transcriptase inhibitor is AZT.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the non-nucleoside analogue reverse transcriptase inhibitor is nevirapine.

### Claim 15 (depends on 9)

The method according to claim 9, where in the patient-derived acquired immunodeficiency virus is obtained from peripheral blood.

### Claim 16 (depends on 9)

The method according to claim 9, where in the patient-derived acquired immunodeficiency virus is obtained from genital secretion.

### Claim 17 (depends on 9)

The method according to claim 9, where in the patient-derived acquired immunodeficiency virus is obtained from cerebro spinal fluid.

### Claim 18

A method of monitoring the efficacy of antiretroviral therapy in a patient comprising obtaining patient-derived acquired immunodeficiency virus samples before and after initiating antiretroviral therapy and quantitating usage of the CXCR4 and/or CCR5 coreceptor in a population of biological clones derived from each patient-derived acquired immunodeficiency virus sample, whereby a decrease of CXCR4 coreceptor use after initiating antiretroviral therapy indicates that the antiretroviral therapy is effective.

### Claim 19 (depends on 18)

The diagnostic method according to claim 18, wherein the acquired immunodeficiency virus is selected from the group consisting of HIV-1 and HIV-2.

### Claim 20 (depends on 18)

The diagnostic method according to claim 18, wherein the antiretroviral therapy is selected from the group consisting of highly active antiretroviral therapy (HAART), protease inhibitors, fusion inhibitors, integrase inhibitors, coreceptor specific agents, non-nucleoside analogue reverse transcriptase inhibitors and nucleoside analogue reverse transcriptase inhibitors.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the nucleoside analogue reverse transcriptase inhibitor is 3TC.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the nucleoside analogue reverse transcriptase inhibitor is AZT.

### Claim 23 (depends on 20)

The method according to claim 20, wherein the non-nucleoside analogue reverse transcriptase inhibitor is nevirapine.

### Claim 24 (depends on 18)

The method according to claim 18, where in to in the patient-derived acquired immunodeficiency virus is obtained from peripheral blood.

### Claim 25 (depends on 18)

The method according to claim 18, where in the patient-derived acquired immunodeficiency virus is obtained from genital secretion.

### Claim 26 (depends on 18)

The method according to claim 18, where in the patient-derived acquired immunodeficiency virus is obtained from cerebro spinal fluid.

### Claim 27

A method of determining CXCR4 and/or CCR5 co-receptor usage in a patient before initiating antiretroviral therapy comprising the steps of:
1) obtaining patient-derived acquired immunodeficiency virus;
2) deriving biological clones therefrom;
3) assaying the clones for CXCR4 coreceptor use;
4) assaying the clones for CCR5 use; and
5) determining the ratio of virus using the CXCR4 coreceptor compared to virus using the CCR5 coreceptor before initiating antiretroviral therapy,
whereby the CXCR4 and/or CCR5 co-receptor usage of the patient is used to determine a suitable antiretroviral treatment regimen.

### Claim 28 (depends on 27)

The diagnostic method according to claim 27, wherein the acquired immunodeficiency virus is selected from the group consisting of HIV-1 and HIV-2.

### Claim 29 (depends on 27)

The diagnostic method according to claim 27, wherein the antiretroviral therapy is selected from the group consisting of highly active antiretroviral therapy (HAART), protease inhibitors, fusion inhibitors, integrase inhibitors, coreceptor specific agents, non-nucleoside analogue reverse transcriptase inhibitors and nucleoside analogue reverse transcriptase inhibitors.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the nucleoside analogue reverse transcriptase inhibitor is 3TC.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the nucleoside analogue reverse transcriptase inhibitor is AZT.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the non-nucleoside analogue reverse transcriptase inhibitor is nevirapine.

### Claim 33 (depends on 27)

The method according to claim 27, where in the patient-derived acquired immunodeficiency virus is obtained from peripheral blood.

### Claim 34 (depends on 27)

The method according to claim 27, where in the patient-derived acquired immunodeficiency virus is obtained from genital secretion.

### Claim 35 (depends on 27)

The method according to claim 27, where in the patient-derived acquired immunodeficiency virus is obtained from cerebro spinal fluid.

### Claim 36

A method of monitoring the efficacy of antiretroviral therapy in a patient comprising the steps of:
1) obtaining patient-derived acquired immunodeficiency virus before and after initiating antiretroviral therapy,
2) deriving biological clones therefrom;
3) assaying the clones for CXCR4 coreceptor use;
4) assaying the clones for CCR5 use; and
5) determining the ratio of virus using the CXCR4 coreceptor compared to virus using the CCR5 coreceptor before and after initiating antiretroviral therapy,
whereby efficacy of the antiretroviral therapy is directly related to a decrease of CXCR4 coreceptor use after die initiation of the therapy.

### Claim 37 (depends on 36)

The diagnostic method according to claim 36, wherein the acquired immunodeficiency virus is selected from the group consisting of HIV-1 and HIV-2.

### Claim 38 (depends on 36)

The diagnostic method according to claim 36, wherein the antiretroviral therapy is selected from the group consisting of highly active antiretroviral therapy (HAART), protease inhibitors, fusion inhibitors, integrase inhibitors, coreceptor specific agents, non-nucleoside analogue reverse transcriptase inhibitors and nucleoside analogue reverse transcriptase inhibitors.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the nucleoside analogue reverse transcriptase inhibitor is 3TC.

### Claim 40 (depends on 38)

The method according to claim 38, wherein the nucleoside analogue reverse transcriptase inhibitor is AZT.

### Claim 41 (depends on 38)

The method according to claim 38, wherein the non-nucleoside analogue reverse transcriptase inhibitor is nevirapine.

### Claim 42 (depends on 36)

The method according to claim 36, where in the patient-derived acquired immunodeficiency virus is obtained from peripheral blood.

### Claim 43 (depends on 36)

The method according to claim 36, where in the patient-derived acquired immunodeficiency virus is obtained from genital secretion.

### Claim 44 (depends on 36)

The method to claim 36, where in the patient-derived acquired immunodeficiency virus is obtained from cerebro spinal fluid.

### Claim 45

A method of determining CXCR4 and/or CCR5 co-receptor usage in a patient-derived acquired immunodeficiency virus sample comprising determining CXCR4 and CCR5 coreceptor use in multiple biological clones derived from the patient-derived acquired immunodeficiency virus sample, and determining a ratio of acquired immunodeficiency virus using the CXCR4 coreceptor compared to virus using the CCR5 coreceptor.

### Claim 46

A method of determining the ratio of CXCR4 to CCR5 co-receptor usage in a patient-derived acquired immunodeficiency virus sample before initiating antiretroviral therapy comprising determining CXCR4 and CCR5 coreceptor use in multiple biological clones derived from the patient-derived acquired immunodeficiency virus sample, and determining the ratio of acquired immunodeficiency virus using the CXCR4 coreceptor compared to virus using the CCR5 coreceptor before initiating antiretroviral therapy, whereby the ratio of CXCR4 to CCR5 co-receptor usage is used to determine a suitable antiretroviral treatment regimen.

### Claim 47

A method of monitoring the efficacy of antiretroviral therapy in a patient comprising determining CXCR4 and CCR5 coreceptor use in multiple biological clones derived from patient-derived acquired immunodeficiency virus samples, and determining the a ratio of acquired immunodeficiency virus using the CXCR4 coreceptor compared to virus using the CCR5 coreceptor after initiating antiretroviral whereby efficacy of the antiretroviral therapy is directly related to a decrease of CXCR4 coreceptor use after initiation of the therapy.

### Claim 48

A method of detecting a shift back in coreceptor usage from the CXCR4 to the CCR5 coreceptor in a patient, comprising determining a first ratio of biological clones derived from a first patient-derived acquired immunodeficiency virus sample using the CXCR4 and CCR5 coreceptor; and determining a second ratio of biological clones derived from a second patient-derived virus sample using the CXCR4 and CCR5 coreceptor; and determining whether there has been a shift back in coreceptor usage from the CXCR4 to the CCR5 coreceptor between the two samples.

### Claim 49 (depends on 48)

The diagnostic method according to claim 48, wherein the acquired immunodeficiency virus is selected from the group consisting of HIV-1 and HIV-2.

### Claim 50 (depends on 48)

The diagnostic method according to claim 48, wherein the patient is undergoing antiretroviral therapy is selected from the group consisting of highly active antiretroviral therapy (HAART), protease inhibitors, fusion inhibitors, integrase inhibitors, coreceptor specific agents, non-nucleoside analogue reverse transcriptase inhibitors and nucleoside analogue reverse transcriptase inhibitors.

### Claim 51 (depends on 50)

The method according to claim 50, whereby the ratios are compared, and a shift back in coreceptor usage from the CXCR4 to the CCR5 coreceptor indicates that the antiretroviral therapy is effective, and no shift back in coreceptor usage from the CXCR4 to the CCR5 coreceptor indicates that the antiretoroviral therapy is not effective.

### Claim 52 (depends on 50)

The method according to claim 50, wherein the nucleoside analogue reverse transcriptase inhibitors is 3TC.

### Claim 53 (depends on 50)

The method according to claim 50, wherein the nucleoside analogue reverse transcriptase inhibitor is AZT.

### Claim 54 (depends on 50)

The method according to claim 50, wherein the non-nucleoside analogue reverse transcriptase inhibitor is nevirapine.

### Claim 55

A method for obtaining a quantitative measurement of the proportion of biological clones derived from a patient-derived acquired immunodeficiency virus sample using the CXCR4 and/or CCR5 coreceptor, wherein the population of virus is expressed as described by the mixture distribution
D=λ(CCR5)+(1−λ)(CXCR4)
where D is the distribution of coreceptor types in the viral pool, λ is the proportion of viral clones that use the CCR5 coreceptor, and 1−λ is the proportion of viral clones that use the CXCR4 coreceptor, and where λ is a continuous non-linear variable with a value from 0 to 1, and wherein λ is described using binomial distribution.

### Claim 56

A method for obtaining a quantitative measurement of the population of virus in a patient-derived acquired immunodeficiency virus sample using the CXCR4 and/or CCR5 coreceptor, comprising:
1) obtaining multiple biological clones from the patient-derived immunodeficiency virus sample,
2) assaying multiple biological clones from the patient-derived immunodeficiency virus samples for CXCR4 coreceptor use;
3) assaying multiple biological clones from patient-derived immunodeficiency virus samples for CCR5 coreceptor use; and
4) scoring each biological clone as either utilizing the CXCR4 coreceptor or the CCR5 coreceptor,
whereby the population of virus in the patient-derived acquired immunodeficiency virus sample using the CXCR4 and/or CCR5 coreceptor can be described by the mixture distribution
D=λ(CCR5)+(1−λ)(CXCR4)
where D is the distribution of coreceptor types in the viral pool, λ is fit proportion of viral clones that use the CCR5 coreceptor, and 1−λ is the proportion of viral clones that use the CXCR4 coreceptor, and where λ is a continuous non-linear variable with a value from 0 to 1, and wherein λ is described using binomial distribution.

### Claim 57

A method for detecting a shift in the proportion of virus using the CXCR4 and/or CCR5 coreceptor over time in a given patient, comprising:
1) obtaining two or more patient-derived acquired immunodeficiency virus samples collected from the patient at different times;
2) obtaining multiple biological clones from each patient-derived immunodeficiency virus sample;
3) assaying multiple biological clones from each patient-derived immunodeficiency virus sample for CXCR4 coreceptor use;
4) assaying multiple biological clones from each patient-derived immunodeficiency virus sample for CCR5 coreceptor use;
5) determining the proportion of biological clones in each patient-derived immunodeficiency virus sample using the CXCR4 and CCR5 coreceptor;
6) generating a value for use of the CCR5 coreceptor in each patient-derived immunodeficiency virus sample, λ,_where the coreceptor usage of the patient-derived virus sample can be described by the mixture distribution;
D=λ(CCR5)+(1−λ)(CXCR4)
where D is the distribution of coreceptor types in the viral pool, and 1−λ is the proportion of viral clones that used the CXCR4 coreceptor, and where λ is a continuous non-linear variable having a value between 0 and 1, and wherein λ is described using binomial distribution;
7) performing binomial proportion comparison tests between time points to detect any shifts in coreceptor usage over time;
8) transforming the binomial distribution data to approximate a Poisson distribution, and
9) performing Poisson regression analysis to determine factors relating to changes in λ values,
whereby shifts in the proportion of virus using the CXCR4 and/or CCR5 coreceptor over time in a given patient are detected.
